14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 09, 2026
ACHV vs TBPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 09, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).
Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.9% vs. 0.0% operating margin) and revenue trajectory (-20.9% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs TBPH. Trailing 12-month operating profitability (ACHV 0.0% vs TBPH 8.9%) and valuation multiples (ACHV 35.3x vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment66.2% of Rev ($69M)
90D Engineering Disclosures0 Published
Investor FAQ ACHV vs TBPH Key Questions & Quantitative Answers
As of Nov 09, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Achieve Life Sciences, Inc. (ACHV) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACHV carries a Unified Composite Score of 56.6/100 (HOLD) at $6.78 (35.3x Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Composite vs. Pillar Nuance: While ACHV currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. TBPH 54.9/100 HOLD), TBPH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.9% vs. 0.0% operating margin) and revenue trajectory (-20.9% vs. +0.0% YoY).
TBPH leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.
TBPH screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus TBPH (20.9% ROE) capital efficiency.
In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 09, 2026. For educational research only; not investment advice.